Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: Experience on 137 patients

Urology

Volumn 52, Issue 5, 1998, Pages 793-796

  Serretta, Vincenzo ^a   Lo Presti, Domenico ^a   Vasile, Pasquale ^a   Gange, Ercole ^a   Esposito, Elisa ^a   Menozzi, Italo ^a  

^a Civic Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EPIRUBICIN; MATRIX PROTEIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0031791985     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00332-X     Document Type: Article

References (13)

1. Murphy W.M. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol. 21:1990;886-890.
2. van der Poel H.G., Oosterhof G.O., Debruyne F.M., et al. Image analysis in superficial transitional cell carcinoma of the bladder. Semin Urol. 11:1993;164-167.
3. Gregoire M., Fradet Y., Meyer F., et al. Diagnostic accuracy of urinary cytology and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol. 157:1997;1660-1664.
4. Shiina H., Igawa M., Nagami H., et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer. 15:1996;1762-1774.
5. Ick K., Stout P., Fan K., et al. The significance of p53 overexpression in transitional cell carcinoma in situ. J Urol. 155:1996;665-669.
6. D'Hallewin M.A., Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol. 155:1996;475-476.
7. Sarosdy M.F., deVere White R.W., Soloway M.S., et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol. 154:1995;379-383.
8. Keesee S, Briggman JB, Thill G, et al: Utilization of nuclear matrix proteins for cancer diagnosis, in, Stein G (Ed): Critical Review in Eukariotic Gene Expression. Baltimore: 1996, vol 6, pp 189-214.
9. Getzenberg R.H., Konety B.R., Oeler T.A., et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 56:1996;1690-1694.
10. Soloway M.S., Briggman V., Carpinito G.A., et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 156:(Pt 1):1996;363-367.
11. Carpinito G.A., Stadler W.M., Briggman J.V., et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 156:1996;1280-1285.
12. Miyanaga N., Akaza H., Ishikawa S., et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol. 31:1997;163-168.
13. Chen Y., Hayden C.L., Marchand K.J., et al. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J Urol. 158:1997;1899-1901.